<unk>  is a novel, highly fibrin-specific "clot-busting" (thrombolytic) drug in development that reached phase III clinical trials. The Danish pharmaceutical company, Lundbeck, owns the worldwide rights to<unk> . In 2009, two large trials (DIAS-3 and DIAS-4) were started to test it as a safe and effective treatment for patients with acute ischaemic stroke. After disappointing results in DIAS-3, DIAS-4 was terminated, and in December 2014 Lundbeck announced that they would stop the development of<unk> .<unk>  is a recombinant form of the alpha-1 isoform of DSPA (Desmodus rotundus salivary plasminogen activator).
Desmoteplase
Tenecteplase
Alteplase
Lusutrombopag
Prokarin
Defibrotide
Ticlopidine
Argatroban